Technical Analysis for DAWN - Day One Biopharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 15.19 | -8.71% | -1.45 |
DAWN closed down 8.71 percent on Wednesday, April 24, 2024, on 4.76 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
Earnings due: May 9
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Flat | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bearish Engulfing | Bearish | 0.00% | |
| Fell Below 50 DMA | Bearish | 0.00% | |
| 20 DMA Support | Bullish | 0.00% | |
| Volume Surge | Other | 0.00% | |
| 50 DMA Support | Bullish | -8.71% | |
| MACD Bullish Centerline Cross | Bullish | -8.71% | |
| Expansion Pivot Buy Setup | Bullish Swing Setup | -8.71% | |
| Pocket Pivot | Bullish Swing Setup | -8.71% | |
| Volume Surge | Other | -8.71% | |
| Wide Range Bar | Range Expansion | -8.71% |
| Alert | Time |
|---|---|
| 20 DMA Support | about 10 hours ago |
| Fell Below Previous Day's Low | about 10 hours ago |
| Down 10% | about 10 hours ago |
| Fell Below 50 DMA | about 10 hours ago |
| Possible Inside Day | about 10 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Enzymes Protein Kinase Inhibitor Signal Transduction Protein Kinase Kinase Ym Biosciences
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Enzymes Protein Kinase Inhibitor Signal Transduction Protein Kinase Kinase Ym Biosciences
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 17.85 |
| 52 Week Low | 9.67 |
| Average Volume | 970,042 |
| 200-Day Moving Average | 13.54 |
| 50-Day Moving Average | 15.22 |
| 20-Day Moving Average | 15.02 |
| 10-Day Moving Average | 14.91 |
| Average True Range | 1.04 |
| RSI (14) | 50.98 |
| ADX | 20.36 |
| +DI | 30.10 |
| -DI | 12.63 |
| Chandelier Exit (Long, 3 ATRs) | 14.28 |
| Chandelier Exit (Short, 3 ATRs) | 16.68 |
| Upper Bollinger Bands | 16.77 |
| Lower Bollinger Band | 13.28 |
| Percent B (%b) | 0.55 |
| BandWidth | 23.29 |
| MACD Line | 0.09 |
| MACD Signal Line | -0.07 |
| MACD Histogram | 0.1575 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 17.86 | ||||
| Resistance 3 (R3) | 18.08 | 17.42 | 17.42 | ||
| Resistance 2 (R2) | 17.42 | 16.74 | 17.31 | 17.27 | |
| Resistance 1 (R1) | 16.30 | 16.32 | 15.97 | 16.08 | 17.12 |
| Pivot Point | 15.64 | 15.64 | 15.47 | 15.53 | 15.64 |
| Support 1 (S1) | 14.52 | 14.96 | 14.19 | 14.30 | 13.26 |
| Support 2 (S2) | 13.86 | 14.54 | 13.75 | 13.11 | |
| Support 3 (S3) | 12.74 | 13.86 | 12.97 | ||
| Support 4 (S4) | 12.52 |
